Breaking the mold: Overcoming resistance to immune checkpoint inhibitors

被引：3
|
作者：
Zhao, Menglu [1 ]
Yan, Chun-Yan [1 ]
Wei, Ya-Nan [1 ]
Zhao, Xi-He [1 ]
机构：
[1] China Med Univ, Shengjing Hosp, Dept Clin Oncol, Shenyang 110022, Peoples R China
来源：
ANTIVIRAL RESEARCH | 2023年 / 219卷
基金：
中国国家自然科学基金;
关键词：
PD-L1; Drug resistance; Bispecific antibody; Antibody drug conjugate (ADC); TUMOR MUTATIONAL BURDEN; T-CELLS; ANTITUMOR IMMUNITY; CANCER; IMMUNOTHERAPY; BLOCKADE; EFFICACY; RECEPTOR; PD-L1; EXPRESSION;
D O I：
10.1016/j.antiviral.2023.105720
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Immune checkpoint blockade-based therapies are effective against a sorts of cancers. However, drug resistance is a problem that cannot be ignored. This review intends to elucidate the mechanisms underlying drug tolerance induced by PD-1/PD-L1 inhibitors, as well as to outline proposed mechanism-based combination therapies and small molecule drugs that target intrinsic immunity and immune checkpoints. According to the differences of patients and types of cancer, the optimization of individualized combination therapy will help to enhance PD-1/ PD-L1-mediated immunoregulation, reduce chemotherapy resistance, and provide new ideas for chemotherapyresistant cancer.
引用
收藏
页数：11
相关论文
共 50 条
  • [21] Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
    Marchini, Antonio
    Scott, Eleanor M.
    Rommelaere, Jean
    VIRUSES-BASEL, 2016, 8 (01):
  • [22] Patient-Specific Humanized PDX Model for Overcoming Tumor Resistance to Immune Checkpoint Inhibitors in NSCLC Patients
    Sobarzo, A.
    Roisman, L.
    Pikovsky, O.
    Atlas, L.
    Christopoulos, P.
    Sultmann, H.
    Peled, N.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S24 - S24
  • [23] Overcoming resistance to immune checkpoint blockade with RNA-loaded nanoparticles
    Sayour, Elias Joseph
    Grippin, Adam
    Mitchell, Duane Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [24] Mechanisms of primary resistance to immune checkpoint inhibitors in Melanoma
    Moogk, Duane
    Wang, Lin
    Li, Kaitao
    Yuan, Zhou
    Zhong, Shi
    Yu, Zhiya
    Liadi, Ivan
    Rittase, William
    Fang, Victoria
    Dougherty, Janna
    Perez-Garcia, Arianne
    Varadarajan, Navin
    Restifo, Nicholas P.
    Frey, Alan
    Osman, Iman
    Weber, Jeff
    Zhu, Cheng
    Krogsgaard, Michelle
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17
  • [25] Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
    Davidson, Tara
    Zhang, Henan
    Dong, Haidong
    Grams, Michael P.
    Park, Sean S.
    Yan, Yiyi
    ADVANCES IN RADIATION ONCOLOGY, 2021, 7 (04)
  • [26] Resistance mechanisms to immune checkpoint inhibitors: updated insights
    Alsaafeen, Besan H.
    Ali, Bassam R.
    Elkord, Eyad
    MOLECULAR CANCER, 2025, 24 (01)
  • [27] Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC
    Gomatou, Georgia
    Charpidou, Andriani
    Li, Peifeng
    Syrigos, Nikolaos
    Gkiozos, Ioannis
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, : 1426 - 1437
  • [28] Temozolomide overcoming resistance to immune checkpoint inhibitors in relapsed/refractory metastatic melanoma? Insights from a single center series
    Dasanu, Constantin A.
    Plaxe, Steven C.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025, 31 (02) : 321 - 324
  • [29] Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition
    Zhao, Manzhi
    Li, Ling
    Kiernan, Caoimhe H.
    Eiro, Melisa D. Castro
    Dammeijer, Floris
    van Meurs, Marjan
    Brouwers-Haspels, Inge
    Wilmsen, Merel E. P.
    Grashof, Dwin G. B.
    van de Werken, Harmen J. G.
    Hendriks, Rudi W.
    Aerts, Joachim G.
    Mueller, Yvonne M.
    Katsikis, Peter D.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [30] Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
    Kim, Hye-Jung
    Cantor, Harvey
    Cosmopoulos, Kat
    TRENDS IN IMMUNOLOGY, 2020, 41 (10) : 948 - 963
12345